Zobrazeno 1 - 10
of 139
pro vyhledávání: '"High dose influenza vaccine"'
Autor:
Huy Quang Quach, Iana H. Haralambieva, Krista M. Goergen, Diane E. Grill, Jun Chen, Inna G. Ovsyannikova, Gregory A. Poland, Richard B. Kennedy
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Older age (≥ 65 years) is associated with impaired responses to influenza vaccination, leading to the preferential recommendation of MF59-adjuvanted (MF59Flu) or high-dose (HDFlu) influenza vaccines for this age group in the United States.
Externí odkaz:
https://doaj.org/article/ce51629654d646adb5d67b575001e389
Autor:
Alexander Domnich, Giancarlo Icardi, Donatella Panatto, Marianna Scarpaleggia, Carlo-Simone Trombetta, Matilde Ogliastro, Federica Stefanelli, Bianca Bruzzone, Andrea Orsi
Publikováno v:
International Journal of Infectious Diseases, Vol 147, Iss , Pp 107202- (2024)
ABSTRACT: Objectives: In order to support policymakers in allocating resources, we aimed to assess vaccine effectiveness (VE) of inactivated influenza vaccines (IIVs) available for Italian adults in the 2023/2024 season. Methods: A hospital-based tes
Externí odkaz:
https://doaj.org/article/5368a0f73dd448c8b156157cc0a7c644
Autor:
Ian McGovern, Benjamin Chastek, Tim Bancroft, Noah Webb, Mahrukh Imran, Stephen I. Pelton, Mendel D.M. Haag
Publikováno v:
International Journal of Infectious Diseases, Vol 146, Iss , Pp 107160- (2024)
Objectives: This study evaluated relative vaccine effectiveness (rVE) of MF59-adjuvanted trivalent inactivated influenza vaccine (aTIV) vs high-dose trivalent inactivated influenza vaccine (HD-TIV) for prevention of test-confirmed influenza emergency
Externí odkaz:
https://doaj.org/article/ba74f04987d645e59bb10f9679ce77ec
Autor:
Kenneth E. Schmader, Christine K. Liu, Brendan Flannery, Wes Rountree, Heidi Auerbach, Elizabeth D. Barnett, Elizabeth P. Schlaudecker, Christopher A. Todd, Marek Poniewierski, Mary A. Staat, Theresa Harrington, Rongxia Li, Karen R. Broder, Emmanuel B. Walter
Publikováno v:
Immunity & Ageing, Vol 20, Iss 1, Pp 1-11 (2023)
Abstract Background Adjuvanted inactivated influenza vaccine (aIIV) and high-dose inactivated influenza vaccine (HD-IIV) are U.S.-licensed for adults aged ≥ 65 years. This study compared serum hemagglutination inhibition (HAI) antibody titers for t
Externí odkaz:
https://doaj.org/article/275af69609234cc6b4651fc11dd8d745
Autor:
C. Raina MacIntyre, J. Kevin Yin, Christian Felter, Robert I. Menzies, Edward Thommes, Nathalie Largeron, Aye M. Moa, Mallory Trent, Valentina Costantino, Seulki Choi, Fabián P. Alvarez
Publikováno v:
Vaccine: X, Vol 15, Iss , Pp 100365- (2023)
Background: Standard dose influenza vaccine provides moderate protection from infection, but with lower effectiveness among the elderly. High dose and adjuvanted vaccines (HD-TIV and aTIV) were developed to address this. This study aims to estimate t
Externí odkaz:
https://doaj.org/article/9be6f38f9364482fb3bc6700348632b0
Publikováno v:
Vaccine: X, Vol 14, Iss , Pp 100327- (2023)
This updated systematic review and meta-analysis of randomized and observational studies published up to April 2023 assessed the relative performance of high-dose inactivated influenza vaccine (HD-IIV) and standard-dose influenza vaccines (SD-IIV) ag
Externí odkaz:
https://doaj.org/article/b27162b33b0948658fed84336698e722
Autor:
Alexander Domnich, Chiara de Waure
Publikováno v:
International Journal of Infectious Diseases, Vol 122, Iss , Pp 855-863 (2022)
ABSTRACT: Objectives: MF59-adjuvanted standard-dose and nonadjuvanted high-dose seasonal influenza vaccines have been developed to protect the elderly at high risk of severe complications. This study aimed to summarize the available evidence on the c
Externí odkaz:
https://doaj.org/article/14d28614ca6243eba72987fd9dc49387
Autor:
Luca Pestarino, Alexander Domnich, Andrea Orsi, Federico Bianchi, Elisa Cannavino, Pier Claudio Brasesco, Gianluca Russo, Simone Valbonesi, Giacomo Vallini, Matilde Ogliastro, Giancarlo Icardi
Publikováno v:
Vaccines, Vol 11, Iss 12, p 1748 (2023)
In Italy, several types of seasonal influenza vaccines (SIVs) are available for older adults, but for the 2022/2023 season there were no guidelines on their specific use. This cross-sectional study assessed the frequency and determinants of the use o
Externí odkaz:
https://doaj.org/article/1ba270094b874187a59038becb243e3b
Autor:
Stephanie Pepin, Jean-François Nicolas, Henryk Szymanski, Isabel Leroux-Roels, Thomas Schaum, Marc Bonten, Giancarlo Icardi, Anju Shrestha, Cynthia Tabar, The QHD00011 study team
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 12, Pp 5475-5486 (2021)
A quadrivalent high-dose inactivated influenza vaccine (IIV4-HD) is licensed for adults ≥65 y of age based on immunogenicity and efficacy studies. However, IIV4-HD has not been evaluated in adults aged 60–64 y. This study compared immunogenicity
Externí odkaz:
https://doaj.org/article/00843d9ce111450f920635f631acd873
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.